Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yale Researcher Says Whooping Cough Vaccines Effective, Despite Outbreaks

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Dr. Shapiro’s editorial was published in the Nov. 28 issue of Journal of the American Medical Association.

Despite recent outbreaks of pertussis (whooping cough) - a highly contagious bacterial disease that is preventable by the current pertussis vaccines - Yale researcher Dr. Eugene Shapiro maintains in an editorial that the vaccines are effective and should still be administered.

Shapiro said that although acellular vaccines may be suboptimal, they are still quite effective and should be focused on pregnant women, infants, and caregivers.

“It is most important to try to protect infants, who have the most severe illnesses and highest mortality from pertussis,” said Shapiro, professor of pediatrics.

Shapiro continued, “The highest rates of both hospitalizations and deaths from pertussis occurred in children younger than two months.”

The resurgence of pertussis in the United States, even among those who have been vaccinated in the past, has led many experts to question the long-term duration of immunity.

Published in the Nov. 28 issue of Journal of the American Medical Association (JAMA), Shapiro’s editorial stresses that while there is speculation that the outbreak is linked to the vaccine’s waning immunity over time, there is no definitive evidence that this is the primary or sole reason for increases in reported cases of pertussis.

The original whole-cell pertussis vaccine DTwP, which also included vaccines against diphtheria and tetanus, was introduced for childhood immunization in the 1940s.

But acellular combination pertussis vaccines (DTaP) replaced DTwP in the early 1990s because the whole-cell vaccine had high rates of side-effects such as fever and inflammation at the injection site.

DTaP uses purified components to reduce side-effects, but Shapiro said there is not enough data on the duration of the DTaP vaccine’s immunity.

“There have been periodic outbreaks in the past even with the whole cell vaccine, so there is no way to know for sure that the outbreaks are linked to the accelular vaccine,” he said. “There is no definitive evidence as to why there are increased outbreaks, and there may be multiple reasons for it.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
Tuesday, April 12, 2016
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Wednesday, July 08, 2015
Racial and Economic Gap in Awareness of Lifesaving HPV Vaccine
Research finds worrisome racial, economic, educational, and gender gaps in awareness about the lifesaving vaccine for HPV.
Monday, June 10, 2013
Yale Researchers Trick Bacteria to Deliver a Safer Vaccine
Yale researchers have developed a new trick, using bacteria’s own cellular mistakes to deliver a safe vaccine.
Tuesday, March 19, 2013
Pioneering Yale Immunologist Receives Inaugural NIH Award
Renowned Yale immunologist Ruslan Medzhitov has been awarded the inaugural Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health (FNIH).
Thursday, February 28, 2013
For Drug Makers, New 3-D Control Opens Wealth of Options
Scientists have demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
Monday, February 18, 2013
Yale Scientists Find a Way to Make Disease-Causing Proteins Vulnerable to Drugs
Researchers have identified a novel way to design drugs for previously inaccessible proteins.
Friday, July 27, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!